Savara to present Phase 3 IMPALA-2 molgramostim data in autoimmune pulmonary alveolar proteinosis at ERS 2026
SVRA•Longer-term efficacy, safety and biomarker findings
Data indicate sustained gains in lung function, exercise capacity, and quality of life, supporting molgramostim as a potential long-term treatment option.
Separate analyses point to reductions in disease-related biomarkers, suggesting the therapy may address underlying disease biology.
Savara to present Phase 3 IMPALA-2 data at ERS 2026
Savara flagged new Phase 3 IMPALA-2 data for molgramostim in autoimmune pulmonary alveolar proteinosis at the ERS Congress, Sept. 5-9, 2026.
Results will be presented in the future, including an oral session on Sept. 6 covering longer-term efficacy and safety from the open-label period.
